Oncocyte to Present at the 23rd Annual Needham Virtual Growth Conference

Rhea-AI Summary

Oncocyte Corporation (NYSE American: OCX) announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 15, 2021, at 10:45 AM EST. The conference aims to provide a platform for the company to present its advancements in molecular diagnostics, particularly in cancer care. Investors can register for the conference through the provided link and access a replay of the presentation on Oncocyte's website post-event. The company's innovative products, such as DetermaRx™ for lung cancer recurrence and DetermaIO™ for immunotherapy response, are integral to its mission of enhancing cancer treatment outcomes.

IRVINE, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to present at the 23^rd Annual Needham Virtual Growth Conference.

Presentation details:
Date: January 15, 2021
Time: 10:45am EST

Investors can register for the conference here: https://wsw.com/webcast/needham103/ocx/

Following the conference, a webcast replay of the presentation will be available on the Investor section of the company’s website, www.oncocyte.com.

About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives and improve outcomes by accelerating and optimizing the diagnosis and treatment of cancer. The Company’s tests and services present multiple opportunities to advance cancer care while also driving revenue growth for the Company. Oncocyte recently launched DetermaRx™, a test that identifies early-stage lung cancer patients who are at high risk for cancer recurrence post-resection and predicts benefit from adjuvant chemotherapy. Oncocyte has also launched DetermaIO™, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, as a research use only tool for pharmaceutical and academic clinical trials. The Company also plans to launch monitoring tests including Therasure™-CNI MONITOR, a blood-based immune therapy monitoring test, as a research use tool in 2021. Oncocyte’s pharmaceutical services provide pharmaceutical companies who are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx and DetermaIO are trademarks of Oncocyte Corporation. Therasure is a trademark of Chronix Biomedical Inc.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Communications, LLC
646-751-4366
cait@lifescicomms.com

 

FAQ

When is Oncocyte's presentation at the Needham Virtual Growth Conference?

Oncocyte Corporation is scheduled to present on January 15, 2021, at 10:45 AM EST.

How can investors register for Oncocyte's conference presentation?

Investors can register for the conference through the link provided in the press release.

What is the focus of Oncocyte Corporation's business?

Oncocyte specializes in molecular diagnostics aimed at improving cancer care through innovative testing solutions.

What are DetermaRx™ and DetermaIO™ offered by Oncocyte?

DetermaRx™ identifies lung cancer patients at high risk for recurrence, while DetermaIO™ predicts response to immunotherapies.

Where can I find the webcast of Oncocyte's presentation after the conference?

The webcast replay will be available on the Investor section of Oncocyte's website following the conference.